<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02579980</url>
  </required_header>
  <id_info>
    <org_study_id>AAAO9603</org_study_id>
    <nct_id>NCT02579980</nct_id>
  </id_info>
  <brief_title>Quantitative Imaging Biomarkers for Sarcoma</brief_title>
  <official_title>Development of Quantitative Imaging Biomarkers for Evaluating Sarcoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Unless a cancer quickly gets smaller with radiation or chemotherapy, the investigators cannot
      tell if the treatment is working or not. In this research program, two techniques using
      magnetic resonance imaging (MRI) scanning will be tested in people who have sarcomas, which
      are rare cancers starting in muscle, tendons, and bones. These particular MRI tests are
      called dynamic contrast enhanced MRI and diffusion weighted MRI. These MRI scans allow
      visualization of how sarcomas are different from the normal organs of the body. These MRI
      tests will tell us the location of sarcoma and its proximity to other structures, as well as
      correlation of imaging with pathological characteristics after surgery
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dynamic Contrast Enhanced MRI (DCE-MRI) and Diffusion Weighted MRI (DW-MRI) are imaging
      approaches that are being utilized in preclinical evaluation as well as clinical trials.
      DW-MRI is a technique for quantifying the increase in water diffusion caused by cellular
      necrosis or apoptosis in tumors within days of therapy. DCE-MRI is frequently used in
      preclinical and early clinical trial assessment of anti-angiogenic and vascular disrupting
      compounds, also within hours of therapeutic intervention. Evidence of drug efficacy and
      dose-dependent response has been demonstrated with certain angiogenesis inhibitors. It may
      also provide useful information for identifying early disease progression, independent of the
      treatment modality. While these approaches provide additional functional information, they
      have yet to be validated in sarcoma patients. This study seeks to develop a standardized
      protocol for performing DCE-MRI and DW-MRI and implement this in a clinical trial of patients
      with sarcomas who will have surgical resection as part of their standard care. This will
      allow the accuracy of in vivo MRI measurements to be directly compared to histology as ground
      truth. The study will also determine the reproducibility of these techniques using repeat
      baseline imaging as well as evaluate the quantitative changes in these parameters before and
      after therapy and correlate with histopathology. The collaboration between Columbia
      University and the University of Utah for this project will allow the existing quantitative
      MRI approaches to be expanded to a multi-center setting, and will establish a paradigm
      infrastructure for future expansion to larger scale multi-center therapeutic trials in
      sarcoma.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation coefficient of Ktrans (DCE MR parameter) and ADC (DWI MR parameter) with microvessel density obtained from histopathology.</measure>
    <time_frame>through study completion, an average of 4 weeks</time_frame>
    <description>The primary endpoint of this study is to evaluate the correlation of the estimated in vivo Dynamic Contrast Enhanced and Diffusion weighted MRI parameters with ex vivo histopathologic measurements obtained from tumor tissue. Correlation coefficient (range: -1 to 1).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Sarcoma</condition>
  <arm_group>
    <arm_group_label>DCE and DWI MRI group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will undergo a baseline MR exam at enrollment within 4 weeks prior to scheduled surgery, which will include DW-MRI and DCE-MRI prior to surgery and tumor tissue collection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>DCE and DWI MRI</intervention_name>
    <description>Dynamic Contrast Enhanced MRI (DCE-MRI) and Diffusion Weighted MRI (DW-MRI): DW-MRI is a technique for quantifying the increase in water diffusion caused by cellular necrosis or apoptosis in tumors within days of therapy. DCE-MRI is frequently used in preclinical and early clinical trial assessment of anti-angiogenic and vascular disrupting compounds, also within hours of therapeutic intervention.</description>
    <arm_group_label>DCE and DWI MRI group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <description>Standard of care procedure for sarcoma patients</description>
    <arm_group_label>DCE and DWI MRI group</arm_group_label>
    <other_name>Tumor resection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>Standard of care procedure for sarcoma patients</description>
    <arm_group_label>DCE and DWI MRI group</arm_group_label>
    <other_name>Magnetic resonance imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  New diagnosis of de novo sarcoma of all histologies (including soft tissue sarcoma,
             osteosarcoma, Ewing sarcoma, and chondrosarcoma) confirmed by biopsy

          -  Scheduled to be treated with surgical resection at the sarcoma or cancer center of
             participating sites

          -  Availability of the patient's medical information

          -  Provide written informed consent for the study

          -  Eighteen years of age or older

          -  Ability to remain motionless in MRI scanner for approximately 40 minutes

        Exclusion Criteria:

          -  Patients with contra-indications for contrast enhanced MR exam, including:

               -  Cardiac pacemaker or pacemaker wiring in situ

               -  Cerebral clips or metal artificial cardiac valves

               -  Ossicle prosthesis

               -  Conditions that could produce a dangerous situation in the presence of a strong
                  magnetic field: line metallic implants, shrapnel, inability to lie still, and
                  conditions that can worsen inside confined spaces (severe claustrophobia,
                  psychosis)

               -  Acute or chronic severe renal disease as determined by glomerular filtration rate
                  (GFR) &lt; 30 ml/min/1.73m2

               -  Pregnancy or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lawrence H Schwartz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>James Picker Professor and Chairman Department of Radiology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lawrence H Schwartz, MD</last_name>
    <phone>(212) 305-8994</phone>
    <email>lhs2120@cumc.columbia.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lawrence H Schwartz, MD</last_name>
      <phone>212-305-8994</phone>
      <email>lhs2120@cumc.columbia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sachin Jambawalikar, PhD</last_name>
      <phone>212-305-5005</phone>
      <email>sj2532@columbia.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute, University of Utah</name>
      <address>
        <city>Salt Lake City,</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey T Yap, PhD</last_name>
      <phone>801-213-5650</phone>
      <email>jeffrey.yap@hci.utah.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://qibawiki.rsna.org/index.php?title=DCE-MRI_tech_ctte</url>
    <description>DCE-MRI Technical Committee. DCE-MRI Quantification Profile, Quantitative Imaging Biomarkers Alliance. Version 1.0. Publicly Reviewed Version. QIBA.</description>
  </link>
  <reference>
    <citation>Jacobs MA, Herskovits EH, Kim HS. Uterine fibroids: diffusion-weighted MR imaging for monitoring therapy with focused ultrasound surgery--preliminary study. Radiology. 2005 Jul;236(1):196-203.</citation>
    <PMID>15987974</PMID>
  </reference>
  <reference>
    <citation>Castillo M, Arbelaez A, Smith JK, Fisher LL. Diffusion-weighted MR imaging offers no advantage over routine noncontrast MR imaging in the detection of vertebral metastases. AJNR Am J Neuroradiol. 2000 May;21(5):948-53.</citation>
    <PMID>10815675</PMID>
  </reference>
  <reference>
    <citation>Chenevert TL, Meyer CR, Moffat BA, Rehemtulla A, Mukherji SK, Gebarski SS, Quint DJ, Robertson PL, Lawrence TS, Junck L, Taylor JM, Johnson TD, Dong Q, Muraszko KM, Brunberg JA, Ross BD. Diffusion MRI: a new strategy for assessment of cancer therapeutic efficacy. Mol Imaging. 2002 Oct;1(4):336-43. Review.</citation>
    <PMID>12926229</PMID>
  </reference>
  <reference>
    <citation>Ei Khouli RH, Jacobs MA, Mezban SD, Huang P, Kamel IR, Macura KJ, Bluemke DA. Diffusion-weighted imaging improves the diagnostic accuracy of conventional 3.0-T breast MR imaging. Radiology. 2010 Jul;256(1):64-73. doi: 10.1148/radiol.10091367.</citation>
    <PMID>20574085</PMID>
  </reference>
  <reference>
    <citation>Herneth AM, Friedrich K, Weidekamm C, Schibany N, Krestan C, Czerny C, Kainberger F. Diffusion weighted imaging of bone marrow pathologies. Eur J Radiol. 2005 Jul;55(1):74-83. Review.</citation>
    <PMID>15921871</PMID>
  </reference>
  <reference>
    <citation>Jacobs MA, Ouwerkerk R, Kamel I, Bottomley PA, Bluemke DA, Kim HS. Proton, diffusion-weighted imaging, and sodium (23Na) MRI of uterine leiomyomata after MR-guided high-intensity focused ultrasound: a preliminary study. J Magn Reson Imaging. 2009 Mar;29(3):649-56. doi: 10.1002/jmri.21677.</citation>
    <PMID>19243047</PMID>
  </reference>
  <reference>
    <citation>Jin G, An N, Jacobs MA, Li K. The role of parallel diffusion-weighted imaging and apparent diffusion coefficient (ADC) map values for evaluating breast lesions: preliminary results. Acad Radiol. 2010 Apr;17(4):456-63. doi: 10.1016/j.acra.2009.12.004.</citation>
    <PMID>20207316</PMID>
  </reference>
  <reference>
    <citation>Mintorovitch J, Moseley ME, Chileuitt L, Shimizu H, Cohen Y, Weinstein PR. Comparison of diffusion- and T2-weighted MRI for the early detection of cerebral ischemia and reperfusion in rats. Magn Reson Med. 1991 Mar;18(1):39-50.</citation>
    <PMID>2062240</PMID>
  </reference>
  <reference>
    <citation>Moseley ME, Kucharczyk J, Mintorovitch J, Cohen Y, Kurhanewicz J, Derugin N, Asgari H, Norman D. Diffusion-weighted MR imaging of acute stroke: correlation with T2-weighted and magnetic susceptibility-enhanced MR imaging in cats. AJNR Am J Neuroradiol. 1990 May;11(3):423-9.</citation>
    <PMID>2161612</PMID>
  </reference>
  <reference>
    <citation>Babsky AM, Topper S, Zhang H, Gao Y, James JR, Hekmatyar SK, Bansal N. Evaluation of extra- and intracellular apparent diffusion coefficient of sodium in rat skeletal muscle: effects of prolonged ischemia. Magn Reson Med. 2008 Mar;59(3):485-91. doi: 10.1002/mrm.21568.</citation>
    <PMID>18306401</PMID>
  </reference>
  <reference>
    <citation>Le Bihan D, Breton E, Lallemand D, Aubin ML, Vignaud J, Laval-Jeantet M. Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology. 1988 Aug;168(2):497-505.</citation>
    <PMID>3393671</PMID>
  </reference>
  <reference>
    <citation>Le Bihan D, Breton E, Lallemand D, Grenier P, Cabanis E, Laval-Jeantet M. MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders. Radiology. 1986 Nov;161(2):401-7.</citation>
    <PMID>3763909</PMID>
  </reference>
  <reference>
    <citation>Szafer A, Zhong J, Gore JC. Theoretical model for water diffusion in tissues. Magn Reson Med. 1995 May;33(5):697-712.</citation>
    <PMID>7596275</PMID>
  </reference>
  <reference>
    <citation>Knight RA, Ordidge RJ, Helpern JA, Chopp M, Rodolosi LC, Peck D. Temporal evolution of ischemic damage in rat brain measured by proton nuclear magnetic resonance imaging. Stroke. 1991 Jun;22(6):802-8.</citation>
    <PMID>2057981</PMID>
  </reference>
  <reference>
    <citation>Jacobs MA, Ouwerkerk R, Wolff AC, Stearns V, Bottomley PA, Barker PB, Argani P, Khouri N, Davidson NE, Bhujwalla ZM, Bluemke DA. Multiparametric and multinuclear magnetic resonance imaging of human breast cancer: current applications. Technol Cancer Res Treat. 2004 Dec;3(6):543-50.</citation>
    <PMID>15560711</PMID>
  </reference>
  <reference>
    <citation>Kamel IR, Bluemke DA, Eng J, Liapi E, Messersmith W, Reyes DK, Geschwind JF. The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma. J Vasc Interv Radiol. 2006 Mar;17(3):505-12.</citation>
    <PMID>16567675</PMID>
  </reference>
  <reference>
    <citation>Chenevert TL, Stegman LD, Taylor JM, Robertson PL, Greenberg HS, Rehemtulla A, Ross BD. Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst. 2000 Dec 20;92(24):2029-36.</citation>
    <PMID>11121466</PMID>
  </reference>
  <reference>
    <citation>Hosseinzadeh K, Schwarz SD. Endorectal diffusion-weighted imaging in prostate cancer to differentiate malignant and benign peripheral zone tissue. J Magn Reson Imaging. 2004 Oct;20(4):654-61.</citation>
    <PMID>15390142</PMID>
  </reference>
  <reference>
    <citation>Brunberg JA, Chenevert TL, McKeever PE, Ross DA, Junck LR, Muraszko KM, Dauser R, Pipe JG, Betley AT. In vivo MR determination of water diffusion coefficients and diffusion anisotropy: correlation with structural alteration in gliomas of the cerebral hemispheres. AJNR Am J Neuroradiol. 1995 Feb;16(2):361-71. Erratum in: AJNR Am J Neuroradiol 1995 Jun-Jul;16(6):1384.</citation>
    <PMID>7726086</PMID>
  </reference>
  <reference>
    <citation>Herneth AM, Philipp MO, Naude J, Funovics M, Beichel RR, Bammer R, Imhof H. Vertebral metastases: assessment with apparent diffusion coefficient. Radiology. 2002 Dec;225(3):889-94.</citation>
    <PMID>12461275</PMID>
  </reference>
  <reference>
    <citation>Hylton N. Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker. J Clin Oncol. 2006 Jul 10;24(20):3293-8. Review.</citation>
    <PMID>16829653</PMID>
  </reference>
  <reference>
    <citation>Miller JC, Pien HH, Sahani D, Sorensen AG, Thrall JH. Imaging angiogenesis: applications and potential for drug development. J Natl Cancer Inst. 2005 Feb 2;97(3):172-87. Review.</citation>
    <PMID>15687360</PMID>
  </reference>
  <reference>
    <citation>Padhani AR, Leach MO. Antivascular cancer treatments: functional assessments by dynamic contrast-enhanced magnetic resonance imaging. Abdom Imaging. 2005 May-Jun;30(3):324-41. Review.</citation>
    <PMID>15688112</PMID>
  </reference>
  <reference>
    <citation>Rehman S, Jayson GC. Molecular imaging of antiangiogenic agents. Oncologist. 2005 Feb;10(2):92-103. Review.</citation>
    <PMID>15709211</PMID>
  </reference>
  <reference>
    <citation>Devries AF, Griebel J, Kremser C, Judmaier W, Gneiting T, Kreczy A, Ofner D, Pfeiffer KP, Brix G, Lukas P. Tumor microcirculation evaluated by dynamic magnetic resonance imaging predicts therapy outcome for primary rectal carcinoma. Cancer Res. 2001 Mar 15;61(6):2513-6.</citation>
    <PMID>11289123</PMID>
  </reference>
  <reference>
    <citation>Evelhoch J, Garwood M, Vigneron D, Knopp M, Sullivan D, Menkens A, Clarke L, Liu G. Expanding the use of magnetic resonance in the assessment of tumor response to therapy: workshop report. Cancer Res. 2005 Aug 15;65(16):7041-4.</citation>
    <PMID>16103049</PMID>
  </reference>
  <reference>
    <citation>Evelhoch JL, LoRusso PM, He Z, DelProposto Z, Polin L, Corbett TH, Langmuir P, Wheeler C, Stone A, Leadbetter J, Ryan AJ, Blakey DC, Waterton JC. Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126. Clin Cancer Res. 2004 Jun 1;10(11):3650-7.</citation>
    <PMID>15173071</PMID>
  </reference>
  <reference>
    <citation>Hoskin PJ, Saunders MI, Goodchild K, Powell ME, Taylor NJ, Baddeley H. Dynamic contrast enhanced magnetic resonance scanning as a predictor of response to accelerated radiotherapy for advanced head and neck cancer. Br J Radiol. 1999 Nov;72(863):1093-8.</citation>
    <PMID>10700827</PMID>
  </reference>
  <reference>
    <citation>Kawai A, Sugihara S, Kunisada T, Uchida Y, Inoue H. Imaging assessment of the response of bone tumors to preoperative chemotherapy. Clin Orthop Relat Res. 1997 Apr;(337):216-25.</citation>
    <PMID>9137193</PMID>
  </reference>
  <reference>
    <citation>Vanel D, Lacombe MJ, Couanet D, Kalifa C, Spielmann M, Genin J. Musculoskeletal tumors: follow-up with MR imaging after treatment with surgery and radiation therapy. Radiology. 1987 Jul;164(1):243-5.</citation>
    <PMID>3588913</PMID>
  </reference>
  <reference>
    <citation>Vanel D, Shapeero LG, Tardivon A, Western A, Guinebretière JM. Dynamic contrast-enhanced MRI with subtraction of aggressive soft tissue tumors after resection. Skeletal Radiol. 1998 Sep;27(9):505-10.</citation>
    <PMID>9809880</PMID>
  </reference>
  <reference>
    <citation>Uhl M, Saueressig U, van Buiren M, Kontny U, Niemeyer C, Köhler G, Ilyasov K, Langer M. Osteosarcoma: preliminary results of in vivo assessment of tumor necrosis after chemotherapy with diffusion- and perfusion-weighted magnetic resonance imaging. Invest Radiol. 2006 Aug;41(8):618-23.</citation>
    <PMID>16829744</PMID>
  </reference>
  <reference>
    <citation>Bartolozzi C, Lencioni R, Caramella D, Mazzeo S, Ciancia EM. Treatment of hepatocellular carcinoma with percutaneous ethanol injection: evaluation with contrast-enhanced MR imaging. AJR Am J Roentgenol. 1994 Apr;162(4):827-31.</citation>
    <PMID>8141000</PMID>
  </reference>
  <reference>
    <citation>Castrucci M, Sironi S, De Cobelli F, Salvioni M, Del Maschio A. Plain and gadolinium-DTPA-enhanced MR imaging of hepatocellular carcinoma treated with transarterial chemoembolization. Abdom Imaging. 1996 Nov-Dec;21(6):488-94.</citation>
    <PMID>8875869</PMID>
  </reference>
  <reference>
    <citation>Murakami T, Nakamura H, Hori S, Tomoda K, Mitani T, Nakanishi K, Hashimoto T, Tsuda K, Kozuka T, Monden M, et al. Detection of viable tumor cells in hepatocellular carcinoma following transcatheter arterial chemoembolization with iodized oil. Pathologic correlation with dynamic turbo-FLASH MR imaging with Gd-DTPA. Acta Radiol. 1993 Jul;34(4):399-403.</citation>
    <PMID>8391291</PMID>
  </reference>
  <reference>
    <citation>Feydy A, Anract P, Tomeno B, Chevrot A, Drapé JL. Assessment of vascular invasion by musculoskeletal tumors of the limbs: use of contrast-enhanced MR angiography. Radiology. 2006 Feb;238(2):611-21. Erratum in: Radiology. 2007 Mar;242(3):950.</citation>
    <PMID>16436820</PMID>
  </reference>
  <reference>
    <citation>Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, Larsson HB, Lee TY, Mayr NA, Parker GJ, Port RE, Taylor J, Weisskoff RM. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging. 1999 Sep;10(3):223-32. Review.</citation>
    <PMID>10508281</PMID>
  </reference>
  <reference>
    <citation>Marcus CD, Ladam-Marcus V, Cucu C, Bouché O, Lucas L, Hoeffel C. Imaging techniques to evaluate the response to treatment in oncology: current standards and perspectives. Crit Rev Oncol Hematol. 2009 Dec;72(3):217-38. doi: 10.1016/j.critrevonc.2008.07.012. Epub 2008 Aug 29. Review.</citation>
    <PMID>18760935</PMID>
  </reference>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 15, 2015</study_first_submitted>
  <study_first_submitted_qc>October 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2015</study_first_posted>
  <last_update_submitted>October 19, 2015</last_update_submitted>
  <last_update_submitted_qc>October 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Lawrence Schwartz</investigator_full_name>
    <investigator_title>James Picker Professor and Chairman Department of Radiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

